US vape promotions: samples, warnings and claims beyond age checks
Verifying that a buyer is an adult does not create a general permission to give away vapes, omit advertising warnings or make lower-risk claims. FDA’s free-sample rule, nicotine-warning requirements and modified-risk framework answer different questions. Genuine, limited business-to-business samples also need to be distinguished from consumer giveaways—not simply labelled “trade only.”
Checked: 20 November 2026 (Asia/Shanghai). This article explains selected US federal promotion rules for consumer ENDS manufacturers, distributors and retailers. The warning examples concern tobacco-derived nicotine ENDS within the regulatory “covered tobacco product” definition; the sampling rule has a broader product reach. This is not approval of a campaign, an individual product determination or a complete federal, state and local advertising guide.
For a vape business, a correctly age-verified customer is only the beginning of a promotional review. Who receives the product, whether it is part of a sale, what appears on the package and advertisement, and what the promotion implies about health can each raise a separate legal issue. A warning or an adults-only audience does not cure a problem under another rule.
An adult-only venue is not a general vape-sampling exception
21 CFR §1140.16(d)(1) prohibits manufacturers, distributors and retailers from distributing, or causing the distribution of, free samples of cigarettes, smokeless tobacco or other tobacco products. The stated exception in paragraph (d)(2) concerns smokeless tobacco in a qualified adult-only facility. It is not a general exception for ENDS at an age-restricted shop or event. Current rule.
FDA’s March 2023 free-samples guidance explains that the prohibition reaches all tobacco products subject to its tobacco authority, including regulated components and parts that do not contain nicotine or are not made or derived from tobacco. It gives atomizers and e-liquids as examples. A product’s being unsuitable for use by itself, or being described as a nicotine-free component, does not alone resolve the sampling question. Guidance, section III.C, printed p.5.
That is not a statement that every object sold by a vape shop is regulated in the same way. The deeming provision excludes accessories of the additionally deemed products, and the product’s actual classification matters. Our US classification and business-role guide addresses that distinction. 21 CFR §1100.2.
A genuine business sample is different from a consumer giveaway
The same FDA guidance says the agency does not consider the regulation to apply to a business distributing a limited quantity to another business as part of a genuine effort to sell or market the product to that business. FDA describes that quantity as no more than necessary for a business or market goal, such as product or inventory selection. Section III.F, printed p.8.
That is FDA’s stated interpretation in nonbinding guidance, not an unrestricted “B2B exemption” written into the regulation. The recipient, commercial purpose and quantity matter. A trade-show badge, company email address or “sample” sticker does not by itself demonstrate that distribution is to a business for that purpose rather than a consumer giveaway.
Nor does this interpretation decide whether the product is lawfully marketable, whether a destination permits its supply or whether a particular shipment may use a carrier. A promotion team should not ask a business-sample description to establish those separate permissions.
“Free” in an offer needs a transaction-level assessment
FDA’s guidance distinguishes prohibited sampling from certain discounts linked to a tobacco-product sale requiring monetary payment. It discusses same-purchase offers such as “two for the price of one,” rather than treating the word “free” as the whole legal test. But giving a consumer a product in exchange for contact details or a mailing-list signup is a nonmonetary exchange that FDA describes as prohibited sampling. Sections III.D–E.1, printed pp.5–7.
Membership and rewards schemes are not a blanket alternative. The guidance discusses whether the product is tied to a qualifying paid transaction and, for certain deferred rewards, whether the recipient can adequately be verified as the original purchaser. Buying membership alone does not turn every later no-charge distribution into a permitted tobacco-product sale. Section III.E.2, printed pp.7–8.
These examples describe FDA’s interpretation of the free-sample prohibition. They do not approve a particular coupon, token-price offer or loyalty design. The guidance expressly notes that state and local laws may restrict prices and coupon redemption, and says potential violations are considered on their specific facts. A conclusion that an offer is not prohibited by this one ban is not clearance of the promotion as a whole.
The package warning does not replace the advertising warning
For nicotine-containing ENDS within the relevant covered tobacco product category, 21 CFR §1143.3 requires:
WARNING: This product contains nicotine. Nicotine is an addictive chemical.
The regulation treats packaging and advertising separately. On packages, the warning area must occupy at least 30% of each of the two principal display panels. For print and other advertisements with a visual component, the warning must occupy at least 20% of the advertisement’s area and appear in its upper portion. The rule expressly gives signs, shelf-talkers, internet webpages and email as examples. A warning printed on the photographed package is not a substitute for checking the advertisement’s own requirements. Section 1143.3(a)–(b).
Those percentages are not a complete artwork specification. The regulation also sets font, contrast, capitalisation, orientation and placement requirements, including an advertising border. A small package does not simply lose its warning obligation: paragraph (d) specifies an outer-container, wrapper or permanently affixed tag arrangement in the stated circumstances.
The scope also differs from the sampling rule. Section 1143.1 excludes a component or part not made or derived from tobacco from its “covered tobacco product” definition. For a nicotine-free product that would otherwise require the warning, §1143.3(c) sets a manufacturer confirmation-and-supporting-data condition and an alternative “This product is made from tobacco.” statement. Merely printing “0 mg” is not the self-certification procedure. Those provisions should not be collapsed into either “every hardware item needs the nicotine warning” or “anything nicotine-free has no labelling obligations.” Definitions; section 1143.3(c).
This discussion does not determine the warning treatment of an individual synthetic-nicotine formulation or component. Non-tobacco nicotine is not outside FDA’s tobacco authority: §1100.2 expressly subjects tobacco products containing nicotine not made or derived from tobacco to chapter IX and its implementing regulations. Product-specific scope must be resolved rather than inferred from a marketing description.
Retailers have specific conditions, not a blanket supplier defence
Section 1143.3(a)(3) protects a retailer from a violation under that section for packaging meeting its conditions: it contains a health warning, comes from the specified manufacturer/importer/distributor with any required licence or permit, and has not been materially altered by the retailer in relation to the warning requirements.
Advertising has a different retailer provision. Paragraph (b)(3) applies paragraph (b) to a retailer if the retailer is responsible for or directs the warning, but it also preserves liability where the retailer displays an advertisement in a location open to the public without a health warning or with a warning the retailer has materially altered. “The supplier made the artwork” is therefore not a universal answer. Section 1143.3(a)(3), (b)(3).
A warning does not authorise a lower-risk claim
Under 21 U.S.C. §387k, introducing a modified-risk tobacco product into interstate commerce requires an effective order under that section. Its definition can reach explicit or implicit representations of lower disease risk or reduced harm, as well as specified reduced-exposure or substance-content representations. The test is not limited to an advertisement containing the exact words “modified risk.” Section 387k(a)–(b).
A PMTA marketing decision under §387j and a modified-risk order under §387k are different decisions. FDA explains that an MRTP order concerns specific products, not an entire product class. A supplier’s general reference to an FDA authorisation—or another product’s order—does not establish permission for the proposed claim on the product being promoted. Premarket review statute; FDA MRTP overview.
This matters beyond the manufacturer. Section 387k(m) separately restricts distributors’ actions reasonably expected to produce the specified consumer beliefs about lower risk, reduced exposure or absence of substances. Adding the nicotine warning does not neutralise the meaning of the rest of a promotion. More generally, false or misleading labelling and advertising can make a tobacco product misbranded under §387c(a)(1) and (7)(A). Distributor provision; misbranding statute.
Smoking-cessation or treatment claims raise a further intended-use question, rather than providing a way around the modified-risk rules. The classification guide linked above explains that separate boundary; this article does not approve therapeutic wording or classify a product as a drug or device.
Review the actual promotion, not one compliance signal
Before relying on an adults-only audience, separate the product’s regulatory category, the recipient and purpose of any no-charge distribution, the applicable package and advertisement warnings, and the meaning and authorisation basis of the claims. None of those questions is answered merely by showing the others have been considered.
Do not copy every cigarette or smokeless-tobacco restriction onto ENDS either. For example, the wording of the federal branded-merchandise and sponsorship provisions in §1140.34 specifically addresses cigarettes and smokeless tobacco. That is a scope distinction—not a finding that a proposed vape sponsorship is lawful under all other rules. Section 1140.34.
Our earlier PMTA and enforcement-policy report separates product-review evidence, policy and court decisions. This promotion-focused account adds another distinction: adult access, lawful distribution, warning compliance and permission for a claim are not interchangeable approvals.